The group organises its work into complementary lines that range from tumour biology to clinical research with patients.
Research lines
Line 1
Molecular basis of tumour progression and therapy resistance
Molecular, cellular and immunological mechanisms that regulate the development, progression and spread of genitourinary tumours, with the aim of identifying new therapeutic targets and understanding what drives tumour aggressiveness and resistance to treatment.
Line 2
Biomarkers and precision medicine in genitourinary cancer
Identification and validation of biomarkers that improve diagnosis, prognosis and treatment selection in patients with genitourinary cancer, contributing to the development of personalised medicine.
Line 3
Therapeutic innovation and clinical research in uro-oncology
Clinical evaluation of new diagnostic and therapeutic strategies through observational studies, clinical trials and translational research, with the aim of improving the management and survival of patients with genitourinary cancer.
